Short answer
KalVista Pharmaceuticals, Inc. (KALV) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$76M
- EPS (diluted)
- −$1.19
Source: XBRL data from the KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 10-Q on SEC EDGAR. USD.
KalVista Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to 10-K risk factors for fiscal year ended April 30, 2025
- Carried-forward risks may materially affect business, financial condition, or operating results
- Newly unknown or currently immaterial risks could adversely affect results
- No new regulatory, legal, operational, competitive, or financial risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other KalVista Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.